CN113116374A - Device and method for detecting fading of ultrasonic contrast agent - Google Patents
Device and method for detecting fading of ultrasonic contrast agent Download PDFInfo
- Publication number
- CN113116374A CN113116374A CN201911395659.0A CN201911395659A CN113116374A CN 113116374 A CN113116374 A CN 113116374A CN 201911395659 A CN201911395659 A CN 201911395659A CN 113116374 A CN113116374 A CN 113116374A
- Authority
- CN
- China
- Prior art keywords
- contrast agent
- characteristic parameter
- ultrasonic contrast
- focal region
- feedback signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002961 echo contrast media Substances 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000005562 fading Methods 0.000 title abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 45
- 238000000605 extraction Methods 0.000 claims abstract description 22
- 238000002592 echocardiography Methods 0.000 claims description 14
- 238000010586 diagram Methods 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 abstract description 3
- 238000009210 therapy by ultrasound Methods 0.000 abstract description 2
- 238000002604 ultrasonography Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Surgical Instruments (AREA)
Abstract
The invention provides a device and a method for detecting fading of an ultrasonic contrast agent, belongs to the technical field of ultrasonic treatment, and can solve the problems that the existing doctor needs to judge the fading condition of the ultrasonic contrast agent according to own experience, and the treatment efficiency and the treatment safety are greatly influenced because the process is not specified in time. The invention relates to a device for detecting fading of an ultrasonic contrast agent, which comprises: the first transceiver unit is used for transmitting a detection signal to focal region tissues injected with ultrasonic contrast agents; receiving a first feedback signal formed by the reflection of the detection signal by focal region tissues injected with the ultrasonic contrast agent; the first extraction unit is used for extracting a first characteristic parameter of the first feedback signal according to the first feedback signal; the comparison unit is used for comparing the first characteristic parameter with a pre-stored initial characteristic parameter and generating a comparison result; and the judging unit is used for judging whether the ultrasonic contrast agent is faded or not according to the comparison result.
Description
Technical Field
The invention belongs to the technical field of ultrasonic treatment, and particularly relates to a device and a method for detecting fading of an ultrasonic contrast agent.
Background
The High Intensity Focused Ultrasound (HIFU) technology has been widely used in the fields of medical treatment, scientific research, material treatment, etc., and it utilizes the focusability and penetrability of ultrasonic waves to focus ultrasonic waves at a specific position after the ultrasonic waves pass through the human body, so that the temperature of the focal region is raised to cause coagulation necrosis, thereby achieving the purpose of treatment. Meanwhile, in the non-focus area, due to the low ultrasonic energy density, normal tissues outside the focus area can be ensured not to be influenced or the influence is acceptable.
In clinic, when HIFU therapy is used, the injection of ultrasound contrast agent is generally used to enhance the medical ultrasound detection signal so as to detect the blood supply condition of the tissue in the treatment area and the treatment effect.
The inventor finds that at least the following problems exist in the prior art: because of the uncontrolled inertial cavitation of ultrasound contrast agents, physicians cannot control the damage caused by ultrasound contrast agents during treatment, and therefore, in general, physicians need to complete metabolism of the contrast agents in the tissue in the region of the isocenter before treatment can begin. However, there is no method and apparatus for detecting whether the ultrasound contrast agent is resolved in the prior art, a doctor needs to judge the resolving condition of the ultrasound contrast agent according to his own experience, and the procedure has no definite time regulation, and if the time is too long, the treatment efficiency is affected, and if the time is too short, the treatment safety is affected.
Disclosure of Invention
The present invention is directed to at least one of the technical problems in the prior art, and provides a device and a method for detecting fading of an ultrasound contrast agent.
The technical scheme adopted for solving the technical problem of the invention is a detection device for fading the ultrasonic contrast agent, which comprises:
the first transceiver unit is used for transmitting a detection signal to focal region tissues injected with ultrasonic contrast agents; and receiving a first feedback signal formed by reflection of the detection signal by the focal region tissue injected with an ultrasonic contrast agent;
a first extraction unit, configured to extract a first characteristic parameter of the first feedback signal according to the first feedback signal;
the comparison unit is used for comparing the first characteristic parameter with a pre-stored initial characteristic parameter and generating a comparison result;
and the judging unit is used for judging whether the ultrasonic contrast agent is faded or not according to the comparison result.
Optionally, the determining unit is specifically configured to:
and if the first characteristic parameter is equal to the pre-stored initial characteristic parameter, determining that the ultrasonic contrast agent is faded.
Optionally, the apparatus for detecting regression of ultrasound contrast agent further comprises:
the second transceiver unit is used for transmitting detection signals to focal region tissues which are not injected with the ultrasonic contrast agent; and receiving a second feedback signal formed by the reflection of the detection signal by the focal region tissue without the injection of the ultrasonic contrast agent;
a second extraction unit, configured to extract a second characteristic parameter of the second feedback signal according to the second feedback signal;
and the storage unit is used for storing the second characteristic parameter as an initial characteristic parameter.
Optionally, the first transceiver unit is specifically configured to:
and transmitting a plurality of focusing pulse waves with the same frequency as the treatment signal to the focal region tissues injected with the ultrasonic contrast agent at preset time intervals.
Optionally, the first transceiver unit is further specifically configured to:
receiving a plurality of first pulse echoes formed by reflection of a plurality of the focused pulse waves by the focal region tissue injected with an ultrasonic contrast agent.
Optionally, the first extracting unit is specifically configured to:
forming a waveform diagram of the first pulse echo according to the first pulse echo;
extracting the amplitude of each first pulse echo according to the oscillogram of the first pulse echo;
a first average of the amplitudes of the first pulse echoes is calculated.
Optionally, the second extraction unit is specifically configured to:
forming a waveform diagram of the second pulse echo according to the second pulse echo;
extracting the amplitude of each second echo according to the oscillogram of the second pulse echo;
a second average of the amplitudes of the plurality of second echoes is calculated.
Optionally, the comparing unit is specifically configured to:
calculating a difference between the first average and the second average; or the like, or, alternatively,
calculating a ratio between the first average value and the second average value; or the like, or, alternatively,
calculating a difference between the integrated value of the first average value and the integrated value of the second average value.
The technical scheme adopted for solving the technical problem of the invention is a detection method for fading of an ultrasonic contrast agent, which comprises the following steps:
transmitting a detection signal to the tissue of the focal region injected with the ultrasonic contrast agent; and receiving a first feedback signal formed by reflection of the detection signal by the focal region tissue injected with an ultrasonic contrast agent;
extracting a first characteristic parameter of the first feedback signal according to the first feedback signal;
comparing the first characteristic parameter with a pre-stored initial characteristic parameter and generating a comparison result;
and judging whether the ultrasonic contrast agent is faded or not according to the comparison result.
Optionally, the determining whether the ultrasound contrast agent is resolved according to the comparison result includes:
and if the first characteristic parameter is equal to the pre-stored initial characteristic parameter, determining that the ultrasonic contrast agent is faded.
Drawings
Fig. 1 is a schematic structural diagram of a device for detecting regression of an ultrasonic contrast agent according to an embodiment of the present invention;
FIG. 2 is a graph showing the pulse echo amplitude variation for patient # I;
FIG. 3 is a graph showing the pulse echo amplitude variation for patient two;
fig. 4 is a schematic flow chart of a method for detecting regression of an ultrasound contrast agent according to an embodiment of the present invention.
Wherein the reference numerals are:
101-a first transceiving unit, 102-a first extraction unit, 103-a comparison unit, 104-a judgment unit, 201-a second transceiving unit, 202-a second extraction unit, and 203-a storage unit.
Detailed Description
In order to make the technical solutions of the present invention better understood, the present invention will be described in further detail with reference to the accompanying drawings and specific embodiments.
Because the HIFU treatment does not require an incision, the safety and effectiveness of the HIFU treatment needs to be determined by means of an imaging tool. Before HIFU treatment is performed, it is necessary to determine the position, size, shape, and the like of the tissue in the treatment region, and also to detect the blood flow supply to the tissue in the treatment region. To facilitate detection of blood flow conditions in the treated tissue, ultrasound contrast agents are typically injected into the treatment area prior to treatment to enhance the acoustic impedance of the blood. However, due to the uncontrollable inertial cavitation of the ultrasound contrast agent, a doctor cannot control the damage condition caused by the ultrasound contrast agent during the treatment process, and for the sake of safety, the injection of the ultrasound contrast agent is generally not used as a means for improving the treatment effect of the HIFU treatment in clinical treatment. In the prior art, before each treatment, a doctor needs to judge the blood supply condition through an ultrasonic contrast agent, and then starts the treatment after the ultrasonic contrast agent for treating the tissues in a focus area is completely metabolized and faded. However, there is no method and apparatus for detecting whether the ultrasound contrast medium is resolved in the prior art, a doctor needs to judge the resolution of the ultrasound contrast medium according to his own experience, and the procedure has no definite time regulation, which greatly affects the treatment efficiency. In order to solve the above problems in the prior art, embodiments of the present invention provide an apparatus and a method for detecting fading of an ultrasound contrast agent, and the apparatus and the method for detecting fading of an ultrasound contrast agent provided in embodiments of the present invention will be described in further detail below with reference to the detailed description and the accompanying drawings.
Example one
Fig. 1 is a schematic structural diagram of a device for detecting regression of an ultrasound contrast agent according to an embodiment of the present invention, and as shown in fig. 1, the device for detecting regression of an ultrasound contrast agent includes: a first transceiver 101, a first extractor 102, a comparator 103 and a determiner 104.
The first transceiver unit 101 is used for transmitting a detection signal to the tissue of the focal region injected with the ultrasonic contrast agent; and receiving a first feedback signal formed by the reflection of the detection signal by the focal region tissue injected with the ultrasonic contrast agent.
It should be noted that the transceiver unit 101 is integrated with a transmitting and receiving function, and can transmit a focused detection signal to a focal region tissue injected with an ultrasound contrast agent, and the transceiver unit 101 may be a transceiver unit in a treatment device, and can transmit a focused detection signal or a treatment signal according to actual needs, where a region focused by the detection signal and a region focused by the treatment signal are the same region. In the embodiment of the present invention, the difference between the detection signal and the treatment signal is that the energy carried by the treatment signal is much higher than the energy carried by the detection signal, so as to avoid the damage of the detection signal to the tissue in the focal region during the detection process, the treatment signal may be a continuous signal, and the detection signal may be a pulse signal. Since all steps of detecting whether the ultrasound contrast agent has faded are performed before treatment, the signals transmitted in the embodiments of the present invention are detection signals carrying lower energy.
It is further noted that the focal region tissue may reflect the detection signal to form a first feedback signal. The ultrasonic contrast agent is a microbubble packaged with gas, so that the acoustic impedance of the tissue of a focus area injected with the ultrasonic contrast agent is different from that of the tissue not injected with the ultrasonic contrast agent, and the ultrasonic contrast agent can greatly enhance the intensity of a first feedback signal formed by the reflection of the tissue of the focus area on a detection signal. Therefore, by comparing the first feedback signal received by the first transceiver unit 101 with the feedback signal formed by the reflection of the tissue without the injected ultrasound contrast agent, it can be determined whether the ultrasound contrast agent in the tissue of the focal region has faded away.
The first extraction unit 102 is configured to extract a first characteristic parameter of the first feedback signal according to the first feedback signal.
It should be noted that the first extracting unit 102 may extract the first characteristic parameter corresponding to the first feedback signal, and the first characteristic parameter may be displayed to the doctor and other medical staff in a graphic, numerical or other form, so as to facilitate the observation of the first feedback signal by the doctor and other medical staff.
The comparing unit 103 is configured to compare the first characteristic parameter with a pre-stored initial characteristic parameter, and generate a comparison result.
It should be noted that the comparing unit 103 may compare the first characteristic parameter with a pre-stored initial characteristic parameter, compare whether the first characteristic parameter and the pre-stored initial characteristic parameter are equal or close, and generate a comparison result. The first characteristic parameter can be used to characterize the content of the ultrasound contrast agent in the current focal region tissue, and the pre-stored initial characteristic parameter can be used to characterize the content of the ultrasound contrast agent in the focal region tissue as 0, i.e. the focal region tissue does not contain the ultrasound contrast agent. In an embodiment of the present invention, the pre-stored initial characteristic parameters may be acquired and stored before the ultrasound contrast agent is injected.
The judging unit 104 is configured to judge whether the ultrasound contrast agent is resolved according to the comparison result.
The determination unit 104 may determine whether the ultrasound contrast medium is resolved based on the generated comparison result. If the judgment unit 10 judges that the ultrasound contrast agent has completely disappeared, the treatment is started. If the judging unit 10 judges that the ultrasound contrast agent is not completely removed, the detecting device for removing the ultrasound contrast agent provided by the embodiment of the invention is used again to detect after a period of time until the ultrasound contrast agent is completely removed, and then the treatment is carried out.
According to the apparatus for detecting regression of ultrasound contrast agent provided in the embodiment of the present invention, based on the principle that acoustic impedances of a tissue in a focal region injected with ultrasound contrast agent are different from acoustic impedances of a tissue without injected with ultrasound contrast agent, the first transceiver 101 may transmit a detection signal to the tissue in the focal region injected with ultrasound contrast agent and receive a first feedback signal formed by reflection of the tissue in the focal region on the detection signal, the first extraction unit 102 may extract a first characteristic parameter corresponding to the first feedback signal, the comparison unit 103 may compare whether a current first characteristic parameter is equal to or close to a pre-stored initial characteristic parameter, and the determination unit 104 may determine whether the contrast agent in the tissue in the focal region is completely regressed. Therefore, doctors can judge the fading condition of the ultrasonic contrast agent without the experience of the doctors, and scientific basis is provided for the detection of the fading of the ultrasonic contrast agent, so that the judgment result is more accurate and visual. Meanwhile, a doctor can more accurately and timely master the fading condition of the ultrasonic contrast agent, so that the detection and monitoring time before treatment can be saved, and the treatment efficiency can be improved. And the danger caused by incomplete regression of the ultrasound contrast agent over too short a time can be avoided.
Optionally, the determining unit 104 is specifically configured to: and if the first characteristic parameter is equal to the pre-stored initial characteristic parameter, determining that the ultrasonic contrast agent is faded.
It should be noted that if the first characteristic parameter is equal to the pre-stored initial characteristic parameter, or the difference between the two is within a certain threshold, i.e. both are close, it indicates that the ultrasound contrast agent in the tissue of the focal region is completely resolved. If the first characteristic parameter is greatly different from the pre-stored initial characteristic parameter, it indicates that more ultrasound contrast agent still remains in the tissue of the focal region, i.e. the ultrasound contrast agent is not completely removed.
As shown in fig. 1, the apparatus for detecting regression of ultrasound contrast agent further includes: a second transceiver 201, a second extraction unit 202 and a storage unit 203.
The second transceiver unit 201 is used for transmitting a detection signal to the focal region tissue without the ultrasonic contrast agent; and receiving a second feedback signal formed by the reflection of the detection signal by the focal region tissue without the injection of the ultrasonic contrast agent.
The second extracting unit 202 is configured to extract a second characteristic parameter of the second feedback signal according to the second feedback signal.
The storage unit 203 is configured to store the second characteristic parameter as an initial characteristic parameter.
It should be noted that the second transceiver 201 and the second extraction unit 202 are similar to the implementation principles of the first transceiver 101 and the first extraction unit 102, and are not described herein again. The difference is that the first parameter feature extracted by the first extraction unit 102 is used for characterizing the content of the ultrasound contrast agent in the current focal region tissue, and the part of the first parameter feature which receives and reflects the detection signal is the focal region tissue injected with the ultrasound contrast agent. The purpose of the second extraction unit 202 for extracting the second parameter features is to characterize the content of the ultrasound contrast agent in the focal region tissue to be 0. The storage unit 203 may store the second parameter characteristic as an initial characteristic parameter, so that the initial characteristic parameter is used as a reference for comparison, and a portion of the initial characteristic parameter, which receives and reflects the detection signal, is a focal region tissue in which the ultrasound contrast agent is not injected.
Optionally, the first transceiver unit 101 is specifically configured to: and transmitting a plurality of focusing pulse waves with the same frequency as the treatment signal to the focal region tissues injected with the ultrasonic contrast agent at preset time intervals.
It should be noted that, in practical applications, the detection signal transmitted by the transceiver 101 may be a focused pulse wave, and the frequency of the focused pulse wave is the same as that of the treatment signal. Specifically, at regular intervals of a preset time, the transceiver unit 101 may transmit a plurality of focused pulse waves with the same frequency as the therapeutic signal to the tissue of the focal region injected with the ultrasound contrast agent, where the focused pulse waves carry low energy, and thus, the tissue of the focal region is ensured not to be damaged. Unlike the focused ultrasound waves emitted by the transceiver unit in the treatment device, the focused ultrasound waves emitted by the transceiver unit in the treatment device are continuous and carry energy large enough to kill the diseased tissue or cells.
Optionally, the first transceiver unit 101 is further specifically configured to: a plurality of first pulse echoes formed by reflection of a plurality of focused pulse waves by focal region tissue injected with an ultrasound contrast agent are received.
It should be noted that the tissue of the focal region injected with the ultrasound contrast agent may reflect the multiple focused pulse waves transmitted by the transceiver unit 101, and form multiple first pulse echoes, where the multiple first pulse echoes are the first feedback signals. It is understood that in the embodiment of the present invention, the detection signal transmitted by the transceiver unit 101 and the received feedback signal are both in the form of pulse waves, and the transceiver unit in the existing therapeutic apparatus integrated with the transmitting and receiving functions may transmit the focused pulse waves for detection and receive the reflected pulse echoes.
Optionally, the first extracting unit 102 is specifically configured to: forming a waveform diagram of the first pulse echo according to the first pulse echo; extracting the amplitude of each first pulse echo according to the oscillogram of the first pulse echo; a first average of the amplitudes of the first pulse echoes is calculated.
It should be noted that the first extraction unit 102 may form a waveform diagram of the received first pulse echo, and the waveform diagram may more intuitively reveal the reflection of the focused pulse wave by the focal region tissue. In the waveform diagram, the first extraction unit 102 may extract the amplitude of the reflected first pulse echo. Since the number of the first pulse echoes is multiple, the first extraction unit 102 may calculate the first average value of the amplitudes of the multiple first pulse echoes, which may improve the accuracy of data and facilitate subsequent comparison of values.
Optionally, the second extracting unit 202 is specifically configured to: forming a waveform diagram of the second pulse echo according to the second pulse echo; extracting the amplitude of each second echo according to the oscillogram of the second pulse echo; a second average of the amplitudes of the second plurality of echoes is calculated.
It should be noted that the implementation principle of the second extraction unit 202 provided in the embodiment of the present invention is similar to that of the first extraction unit 102, and is not described herein again. The purpose is also to extract and compare more accurate values.
Optionally, the comparing unit 103 is specifically configured to: calculating a difference between the first average value and the second average value; or, calculating a ratio between the first average value and the second average value; alternatively, a difference between the integrated value of the first average value and the integrated value of the second average value is calculated.
It should be noted that the comparing unit 103 may calculate a difference value between the first average value and the second average value, and if the difference value is 0, it indicates that the two average values are equal, so that it may be determined that the ultrasound contrast agent in the tissue of the focal region is completely resolved. The comparing unit 103 may also calculate a ratio between the first average value and the second average value, and if the ratio is 1, it indicates that the two are equal, so that it may be determined that the ultrasound contrast agent in the tissue of the focal region is completely resolved. The comparison unit 103 may also determine that the ultrasound contrast agent in the tissue of the focal region is completely resolved if the difference between the integral values of the first average value and the second average value is 0 by calculating the integral value of the first average value and the integral value of the second average value. It is understood that whether the first average value is equal to the second average value can be determined in other ways, which are not listed here.
In a specific example, fig. 2 is a schematic diagram of the amplitude variation of the pulse echo of patient one, as shown in fig. 2, the amplitude of the pulse echo acquired by patient one without injecting ultrasound contrast is 1500 millivolts (mv), after injecting ultrasound contrast agent, the amplitude of the first pulse echo is acquired every 1 minute (min), it can be seen from fig. 2 that along with the metabolism of the ultrasound contrast agent in the tissue of the focal region, the amplitude of the first pulse echo shows a downward trend, and about 15min, the amplitude of the first pulse echo is substantially equal to the amplitude of the pre-stored initial pulse echo, i.e. returns to the level without injecting ultrasound contrast agent, so that it can be determined that the ultrasound contrast agent in the tissue of the focal region is completely faded at this time. However, the ultrasound contrast agent in the tissue of the focal region of each patient is not completely dissolved after 15min, and the blood, physiological parameters and the like of each patient are different, so that the metabolism capability of the ultrasound contrast agent is different. Fig. 3 is a graph showing the amplitude change of the pulse echo of patient two, and as shown in fig. 3, after about 4min for patient two, the amplitude of the first pulse echo is restored to the original level, i.e., the ultrasound contrast agent in the tissue of the focal region in the body of patient two is completely removed after 4 min.
As can be seen from the oscillogram of the first pulse echo of the two-position patient, by using the device for detecting the regression of the ultrasonic contrast agent provided by the embodiment of the invention, a doctor can judge whether the ultrasonic contrast agent in the patient body regresses or not without depending on the experience of the doctor, so that the detection and monitoring time before treatment can be obviously saved, and the treatment efficiency is greatly improved.
Example two
Based on the same inventive concept, an embodiment of the present invention provides a method for detecting regression of an ultrasound contrast agent, fig. 4 is a schematic flow chart of the method for detecting regression of an ultrasound contrast agent provided by the embodiment of the present invention, as shown in fig. 4, the method for detecting regression of an ultrasound contrast agent includes the following steps:
s401, transmitting a detection signal to focal region tissues injected with an ultrasonic contrast agent; and receiving a first feedback signal formed by the reflection of the detection signal by the focal region tissue injected with the ultrasonic contrast agent.
S402, extracting a first characteristic parameter of the first feedback signal according to the first feedback signal.
And S403, comparing the first characteristic parameter with a pre-stored initial characteristic parameter and generating a comparison result.
And S404, judging whether the ultrasonic contrast agent is faded or not according to the comparison result.
Optionally, the step S404 of determining whether the ultrasound contrast agent is resolved according to the comparison result includes:
and if the first characteristic parameter is equal to the pre-stored initial characteristic parameter, determining that the ultrasonic contrast agent is faded.
It should be noted that the method for detecting fading of an ultrasound contrast agent provided in the embodiment of the present invention may be performed by each unit in the apparatus for detecting fading of an ultrasound contrast agent provided in the above embodiment, and the implementation principle is similar, and is not described herein again.
It will be understood that the above embodiments are merely exemplary embodiments taken to illustrate the principles of the present invention, which is not limited thereto. It will be apparent to those skilled in the art that various modifications and improvements can be made without departing from the spirit and substance of the invention, and these modifications and improvements are also considered to be within the scope of the invention.
Claims (10)
1. A device for detecting regression of an ultrasound contrast agent, comprising:
the first transceiver unit is used for transmitting a detection signal to focal region tissues injected with ultrasonic contrast agents; and receiving a first feedback signal formed by reflection of the detection signal by the focal region tissue injected with an ultrasonic contrast agent;
a first extraction unit, configured to extract a first characteristic parameter of the first feedback signal according to the first feedback signal;
the comparison unit is used for comparing the first characteristic parameter with a pre-stored initial characteristic parameter and generating a comparison result;
and the judging unit is used for judging whether the ultrasonic contrast agent is faded or not according to the comparison result.
2. The apparatus according to claim 1, wherein the determining unit is specifically configured to:
and if the first characteristic parameter is equal to the pre-stored initial characteristic parameter, determining that the ultrasonic contrast agent is faded.
3. The apparatus for detecting regression of ultrasound contrast agent according to claim 1, further comprising:
the second transceiver unit is used for transmitting detection signals to focal region tissues which are not injected with the ultrasonic contrast agent; and receiving a second feedback signal formed by the reflection of the detection signal by the focal region tissue without the injection of the ultrasonic contrast agent;
a second extraction unit, configured to extract a second characteristic parameter of the second feedback signal according to the second feedback signal;
and the storage unit is used for storing the second characteristic parameter as an initial characteristic parameter.
4. The apparatus according to claim 3, wherein the first transceiver is specifically configured to:
and transmitting a plurality of focusing pulse waves with the same frequency as the treatment signal to the focal region tissues injected with the ultrasonic contrast agent at preset time intervals.
5. The apparatus according to claim 4, wherein the first transceiver unit is further configured to:
receiving a plurality of first pulse echoes formed by reflection of a plurality of the focused pulse waves by the focal region tissue injected with an ultrasonic contrast agent.
6. The apparatus according to claim 5, wherein the first extraction unit is specifically configured to:
forming a waveform diagram of the first pulse echo according to the first pulse echo;
extracting the amplitude of each first pulse echo according to the oscillogram of the first pulse echo;
a first average of the amplitudes of the first pulse echoes is calculated.
7. The apparatus for detecting regression of ultrasound contrast agent according to claim 6, wherein said second extraction unit is specifically configured to:
forming a waveform diagram of the second pulse echo according to the second pulse echo;
extracting the amplitude of each second echo according to the oscillogram of the second pulse echo;
a second average of the amplitudes of the plurality of second echoes is calculated.
8. The apparatus according to claim 7, wherein the comparing unit is specifically configured to:
calculating a difference between the first average and the second average; or the like, or, alternatively,
calculating a ratio between the first average value and the second average value; or the like, or, alternatively,
calculating a difference between the integrated value of the first average value and the integrated value of the second average value.
9. A method of detecting regression of an ultrasound contrast agent, comprising:
transmitting a detection signal to the tissue of the focal region injected with the ultrasonic contrast agent; and receiving a first feedback signal formed by reflection of the detection signal by the focal region tissue injected with an ultrasonic contrast agent;
extracting a first characteristic parameter of the first feedback signal according to the first feedback signal;
comparing the first characteristic parameter with a pre-stored initial characteristic parameter and generating a comparison result;
and judging whether the ultrasonic contrast agent is faded or not according to the comparison result.
10. The method for detecting the regression of the ultrasound contrast agent according to claim 9, wherein said determining whether the ultrasound contrast agent regresses according to the comparison result includes:
and if the first characteristic parameter is equal to the pre-stored initial characteristic parameter, determining that the ultrasonic contrast agent is faded.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911395659.0A CN113116374A (en) | 2019-12-30 | 2019-12-30 | Device and method for detecting fading of ultrasonic contrast agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911395659.0A CN113116374A (en) | 2019-12-30 | 2019-12-30 | Device and method for detecting fading of ultrasonic contrast agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113116374A true CN113116374A (en) | 2021-07-16 |
Family
ID=76768056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911395659.0A Pending CN113116374A (en) | 2019-12-30 | 2019-12-30 | Device and method for detecting fading of ultrasonic contrast agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113116374A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642607A (en) * | 2009-09-01 | 2010-02-10 | 西安交通大学 | Low-strength focusing ultrasonic medicine release controlling and monitoring device based on array energy transducer |
| CN101917908A (en) * | 2007-12-28 | 2010-12-15 | 博莱科瑞士股份有限公司 | Quantification analisys of immobilized contrast agent in medical imaging applications |
| CN102166135A (en) * | 2010-02-25 | 2011-08-31 | 重庆融海超声医学工程研究中心有限公司 | High-intensity focused ultrasound treatment device |
| CN107693051A (en) * | 2017-07-24 | 2018-02-16 | 复旦大学附属中山医院 | The non-invasive detection system of transplanted kidney immune state |
| CN108289654A (en) * | 2015-12-10 | 2018-07-17 | 博莱科瑞士股份有限公司 | Immobilization contrast agent is detected by dynamic threshold value |
-
2019
- 2019-12-30 CN CN201911395659.0A patent/CN113116374A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101917908A (en) * | 2007-12-28 | 2010-12-15 | 博莱科瑞士股份有限公司 | Quantification analisys of immobilized contrast agent in medical imaging applications |
| CN101642607A (en) * | 2009-09-01 | 2010-02-10 | 西安交通大学 | Low-strength focusing ultrasonic medicine release controlling and monitoring device based on array energy transducer |
| CN102166135A (en) * | 2010-02-25 | 2011-08-31 | 重庆融海超声医学工程研究中心有限公司 | High-intensity focused ultrasound treatment device |
| CN108289654A (en) * | 2015-12-10 | 2018-07-17 | 博莱科瑞士股份有限公司 | Immobilization contrast agent is detected by dynamic threshold value |
| CN107693051A (en) * | 2017-07-24 | 2018-02-16 | 复旦大学附属中山医院 | The non-invasive detection system of transplanted kidney immune state |
Non-Patent Citations (1)
| Title |
|---|
| 燕山，詹维伟: "《浅表器官超声诊断》", 30 June 2005 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10383685B2 (en) | Techniques for use with nerve tissue | |
| JP4686269B2 (en) | Ultrasonic therapy device | |
| US20110251528A1 (en) | Methods and systems for non-invasive treatment of tissue using high intensity focused ultrasound therapy | |
| US20110144490A1 (en) | Devices and methods for adipose tissue reduction and skin contour irregularity smoothing | |
| US20110144545A1 (en) | Methods And System For Delivering Treatment To A Region Of Interest Using Ultrasound | |
| US20040030250A1 (en) | Injection system for gene delivery | |
| CN107106872B (en) | System for ablation or monitoring of a cardiac region by ultrasound | |
| US20100241001A1 (en) | Ultrasound Methods, Systems and Computer Program Products for Imaging Fluids | |
| CN105054972A (en) | Ultrasound diagnosis and treatment system and method for treating tumour by adopting same | |
| CN107261344A (en) | A kind of ultrasonic adapted local cosine transform method for sound dynamic therapy | |
| Erpelding et al. | Mapping age-related elasticity changes in porcine lenses using bubble-based acoustic radiation force | |
| US20200282239A1 (en) | Apparatus, system, and method for mechanical ablation with therapeutic ultrasound | |
| CN113332620A (en) | Ultrasonic medical equipment | |
| CN113116374A (en) | Device and method for detecting fading of ultrasonic contrast agent | |
| US20210015511A1 (en) | System and method for comminution of biomineralizations using microbubbles | |
| US20200139159A1 (en) | Control method for the treatment of brain tissue | |
| CN109381807A (en) | Ultrasonography monitoring system and method, supersonic therapeutic system | |
| CN113117258B (en) | Detection device for tissue coagulation necrosis | |
| CN113116382A (en) | Skin tissue temperature detection device and detection method | |
| CN113117267B (en) | Treatment plan making device | |
| WO2020254419A1 (en) | Method for treating a patient with hifu | |
| CN113117268B (en) | Device for detecting cavitation effect and ultrasonic treatment equipment | |
| EP2698183A2 (en) | Apparatus for ultrasonic therapeutic treatment, and method for driving the apparatus | |
| CN113117262B (en) | Device for detecting cavitation effect and ultrasonic treatment equipment | |
| CN113117257B (en) | Method and device for detecting cavitation effect and ultrasonic treatment equipment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210716 |